Autologous bone marrow-derived mononuclear cells for myocardial infarction

These trials aim to determine the safety and efficacy of autologous bone marrow-derived mononuclear cells (BM-MNCs) which will be concentrated and administrated intracoronarily  to patients with myocardial infarction (MI). The MYSTAR study demonstrated feasibility, safety and efficacy of combined delivery of a large number of autologous BM-MNCs in patients after acute myocardial infarction (AMI), who had severely depressed left ventricular function. Early and late treatment both resulted in improved infarct size and in global ejection fraction (EF). A significant temporary benefit was seen after early therapy, and was nonsignificant by the same timepoint after late therapy. In the 9-12 months after acute MI, a clear and sustained beneficial effect of the combined delivery of the bone-marrow-derived mononuclear cells on left ventricular function in both groups compared with pretreatment values, was observed.